Some 83 percent think Medicare should negotiate prescription drug prices for the Part D program. "The public thinks Medicare should negotiate drug prices just like the agency does for all other medical goods and services," says TSCL's Medicare and Social Security policy analyst, Mary Johnson. A complete repeal of the Affordable Care Act, known as
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February 14, 2017, the plaintiff voluntarily dismissed the putative securities class action lawsuit he had recently filed against the company and certain members of its...
-Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced that they have achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin. Achaogen is developing plazomicin for...
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. In 2017, AmpliPhi plans to initiate phage therapy studies in severa
Analyst Ratings For ANI Pharmaceuticals (NASDAQ:ANIP) Today, ANI Pharmaceuticals (NASDAQ:ANIP) stock was downgraded by Roth Capital from Buy to Neutral with a price target of $69.00. There are 2 hold ratings, 3 buy ratings, 1 strong buy rating on the stock. The current consensus rating on ANI Pharmaceuticals (NASDAQ:ANIP) is Buy (Score: 2.83) with
-Aphios Corporation today announced that it is spinning-off Aphios Pharma to develop FDA- approved, cannabis-based drugs for treating highly unmet Central Nervous System disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
DEAR DOCTOR: I had my thyroid removed because of papillary cancer, and my surgeon has advised me to take high levels of vitamin D. He says there may be a correlation between low vitamin D levels and the development of cancer and Alzheimer's disease. If I remember correctly, the normal blood range for vitamin D is between 30 and 60 nanograms per mil
-Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King`s College London. Professor David E. Thurston of the Institute of Pharmaceutical Science is leading the team at King`s to develop and opti
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
LONDON, UK/ ACCESSWIRE/ February 23, 2017/ Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. as the Company announced on February 22, 2017, that the Company's New Drug Application resubmission for DEXTENZA?, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
CTI BioPharma Corp. today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Thursday, March 2 1:30 p.m. PT/ 4:30 p.m. ET/ 10:30 p.m. CET 1-877-719-9788 +1 719-325-4802. CTI BioPharma Corp. is a biopharmaceutical company focus
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
In Dr. Spykers accomplished career, he held positions as Senior Director of Drug Safety and Pharmacovigilance at Alexza Pharmaceuticals; Director, Pharmacokinetics and Pharmacodynamic Sciences, Genentech, where he established the clinical pharmacology unit; and Senior Medical Director, Clinical Risk Assessment and Coordination Department at Purdue.
Earth Science Tech, Inc., an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidia
Feb. 22 There is plenty of distance between Democrats and Republicans over health coverage Republicans want to dismantle the Affordable Care Act, Democrats want to keep it, and those in both parties who want to fix it can't begin to agree on how. Even President Donald Trump says price-gouging pharmaceutical companies are "getting away with murd